

How we are fueling further exploration for clinicians and scientists



Fotis Vlachos, PhD
Chief Marketing &
Commercial Officer, MR
—
GE HealthCare
London, UK

When we introduced SIGNA™ MAGNUS[†], we embarked on an exploration journey that laid the foundation for groundbreaking neurological discoveries. The FDA-clearance for SIGNA MAGNUS in October 2024, took us one step closer to finding new ways to deal with some of the world's most complex and deteriorating diseases.

What is even more exciting is that MAGNUS was only the beginning. Today, we are thrilled to unveil our latest MR innovation: SIGNA™ Sprint[‡]. SIGNA Sprint earns its name by embodying our mission to rapidly advance MR capabilities and accessibility for patients throughout the world.

SIGNA Sprint exemplifies two key tenets of our mission: to enable groundbreaking discoveries while making MR more accessible and sustainable. Bringing an impressive gradient performance for the first time in a 1.5T scanner and native compatibility with our industry-leading AI solutions, SIGNA Sprint is equipped to deliver exceptional power with brilliant intelligence.

Building on the strong foundation of SIGNA MAGNUS, SIGNA Sprint aims to expand MR's capabilities and applications in two critical care pathways: cardiology and oncology. SIGNA Sprint provides our clinical and academic partners a unique opportunity to tap all the benefits of a 3.0T-like gradient, with the accessibility of a 1.5T system, enabling you to deliver more precise, consistent imaging for patients and research needs. In cardiology, users will recognize the

benefits of 1.5T imaging, coupled with impressively short TRs, delivering advanced clinical care made easy. In oncology, users will enjoy ultra-short TEs to reduce distortion in high-resolution diffusion imaging and compatibility with the AIR™ RT Open Coil Suite of surface coils, designed for use with radiation oncology tools.

SIGNA Sprint is more than just an addition to our product lineup – it's a leap forward in our mission to change the outcome, enabling broader access to the latest technology for more patients and users worldwide.

Together, we are shaping the future of MR imaging, one innovation at a time, so we can leave future generations with a world where healthcare truly has no limits. **S**

[†] SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.

[‡] 510(k) pending at US FDA. Not yet CE marked. Not available for sale.

GE HealthCare welcomes new SIGNA Sprint 1.5T to explore further

GE HealthCare will unveil its latest innovation at the 2025 Annual Meeting of the International Society for Magnetic Resonance in Medicine in Honolulu, Hawaii. Featuring technology and designs that will open new frontiers in diagnostic and research imaging, SIGNA™ Sprint[‡] delivers unparalleled gradient performance at 1.5T to enable a leap forward in key clinical areas, including cardiology and oncology.

In cardiology, the 1.5T field strength ensures the broadest populations of patients can be imaged. Coupled with cutting-edge deep-learning technology like Sonic DL™ for Cine, SIGNA Sprint is designed to aid in standardization in quantitative Cardiac MR. In oncology, SIGNA Sprint seeks to enable earlier disease detection and treatment response through exceptional diffusion imaging, not previously thought possible at 1.5T. Radiotherapy and radiation oncology users will appreciate the advanced gradient technology that is designed to enable precision targeting and treatment

planning using new deep-learning techniques for improving diffusion image quality.

At its core, SIGNA Sprint is designed to provide exceptional power with brilliant intelligence. Tools like Imaging 360 and other clinical efficiency technologies deliver a brilliant experience for users of all levels. Foundational to SIGNA Sprint is patient satisfaction, prioritizing comfort. Our teams look forward to sharing SIGNA Sprint with the world — and sharing our journey as we take MR to places it's never been before. **S**

